SciELO - Scientific Electronic Library Online

 
vol.89 suppl.2Immunogenicity of multiple antigen peptides containing Plasmodium vivax CS epitopes in BALB/c miceAdvances toward the development of an asexual blood stage MSP-1 vaccine of Plasmodium vivax author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Memórias do Instituto Oswaldo Cruz

Print version ISSN 0074-0276On-line version ISSN 1678-8060

Mem. Inst. Oswaldo Cruz vol.89  suppl.2 Rio de Janeiro  1994

http://dx.doi.org/10.1590/S0074-02761994000600018 

A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies

Claude Oeuvray1 

Hasnaa Bouharoun-Tayoun1 

Heléne Grass-Masse2 

Jean Paul Iepers3 

Laurence Ralamboranto3 

André Tartar4 

Pierre Druilhe1 

Institut Pasteur, Laboratoire de Parasitologie Médicale, Paris, France

Institut Pasteur de Lille, Laboratoire de Chimie des Bio-Molécules, Lile, France

URA, CNRS, Lile, France

Institut Pasteur de Madagascar, Unité de Recherche sur le Paludisme, Antananarivo, Madagascar

ABSTRACT

We report the identification of a 48kDa antigen targeted by antibodies which inhibit Plasmodium falciparum in vitro growth by cooperation with blood monocytes in an ADCI assay correlated to the naturally acquired protection. This protein is located on the surface of the merozoite stage of P. falciparum, and is detectable in all isolates tested. Epidemiological studies demonstrated that peptides derived from the amino acid sequence of MSP-3 contain potent B and T-cell epitopes recognized by a majority of individuals living in endemic areas. Moreover human antibodies either purified on the recombinant protein, or on the synthetic peptide MSP-3b, as well as antibodies raised in mice, were all found to promote parasite killing mediated by monocytes.

Key words: malaria; Plasmodium falciparum; merozoite; MSP-3

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License